A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
The US has used its dominant power to enforce the conventions in other countries, in ways that include making financial aid contingent on drug control efforts, and supplying economic and military support for drug intervention. The drug conventions do not explicitly prohibit, they establish control over a set of drugs. The personal use of illicit drugs is not outlawed, although possession is. Penalties are not specified, they are at the discretion of individual countries, and can range from mild to harsh. In practice, this flexibility has been used to create a prohibitionist, punitive war on drugs that is not explicitly required by the treaties. Negative effects of this hardline approach – increased violence and organized crime; human rights violations – have led to an increasing number of countries deviating from the regime. Deviation undermines the credibility of the drug conventions, which in turn, can weaken the entire system of UN international treaties.
== History == Physicians historically used odors as a diagnostic indicator to judge a patient's health. Hippocrates saw the breath of patients as a potential indicator in around 400 BCE. Galen, Avicenna, and other physicians considered urine scent alongside color, density, sediments, and more in urinalysis. Urine with a sweet odor was diagnosed as possessing dominating sanguine humor relative to the other three humors; pungent odor as an excessive amount of bile; and foul odor as the presence of ulcers in the urinary tract or development of putrefactive fever, a fever occurring in the humors. VOCs are currently deemed as noninvasive diagnostic biomarkers with the potential for point-of-care (POC) testing and long-term monitoring.
=== Children === Prolonged use of prednisolone eye drops in children may lead to raised intraocular pressure. While this phenomenon is dose-dependent, it is shown to have a greater effect, especially in children under 6 years of age.
Sources: en.wikipedia.org
2C-B was legitimately marketed and sold as an over-the-counter sexual enhancer under brand names like Erox in several European countries such as Germany in the 1980s and early 1990s. It was manufactured by the German pharmaceutical company Drittewelle and was sold in adult stores, smart shops, and some nightclubs. In addition, 2C-B was sold in Dutch smart shops as an ecstasy-like legal high under names like Nexus. 2C-B was first encountered as a novel recreational designer drug in the United States in 1985. It was advertised and used as an MDMA substitute after MDMA was made illegal around this time. 2C-B has been said to have been legally sold in Southern Africa from 1993 to 1996 and used as an entheogen by the Sangoma, Nyanga, and Amagqirha people in place of their traditional plants; they refer to the chemical as Ubulawu Nomathotholo, which roughly translates to "Medicine of the Singing Ancestors". The drug became a controlled substance in the United States in 1994. It also became a controlled substance in most other countries in the mid-1990s. In addition, 2C-B was placed in Schedule II of the United Nations Convention on Psychotropic Substances and hence became an internationally controlled substance in 2001. Following 2C-B's restriction, many other 2C psychedelics, such as 2C-E and 2C-I, emerged as designer drugs. Nonetheless, 2C-B is the most popular of the 2C psychedelics. Subsequent to their emergence, numerous other 2C drugs besides 2C-B have also been made controlled substances throughout the world.
The Headcrabs have received generally positive reception, identified as a series mascot due to existing merchandise. Kotaku writer Levi Winslow regarded encountering Headcrabs in Half-Life as among the most frightening moments in video games; they felt that the name itself was rather frightening, but the sight of it lunging for the player's head disgusted them. They found it particularly disgusting that, once it latches onto a person, it begins to take over their motor functions. Rock Paper Shotgun writer Adam Smith regarded the Headcrabs as among his favorite video game monsters, stating that they have many of the traits of the best monsters, including being small, hiding in dark spaces, leaping at people's faces, and the ability to turn people into zombies. In particular, the weaponization of Headcrabs in Half-Life 2 struck Smith, feeling that it represented a "credible extension" of the Headcrabs' role from Half-Life. He found the Poison Headcrabs to be particularly frightening, stating that he could not talk about them without "lift[ing] my feet onto the chair" out of anxiety of being bitten by one. Describing the Headcrab as "shamelessly ripped off" from the Facehuggers from the Alien series, GamesRadar+ writer Alex Avard felt that it was one of the most terrifying aliens for a multitude of reasons, including its leap attack, what happens if it latches onto a person's head, and the Headcrabs found in Ravenholm.
=== Allatostatin A === Allatostatin A (AstA) peptides are found in all arthropods and contain a C-terminus Y/FXFGLamide. In Drosophila, there are 4 AstA peptides (AstA-1, AstA-2, AstA-3, AstA-4) and 2 AstA receptors (AstA-R1 and AstA-R2). The AstA receptor is a GIRK1 channel and is homologous to the mammalian galanin receptor
E.; van Donzel, E. & Heinrichs, W. P. (eds.). The Encyclopaedia of Islam, Second Edition. Volume X: T–U. Leiden: E. J. Brill. pp. 763–764. ISBN 978-90-04-11211-7. Wellhausen, Julius (1927). The Arab Kingdom and Its Fall. Translated by Margaret Graham Weir. Calcutta: University of Calcutta.
Sources: en.wikipedia.org
=== Historical sites === Lebanon is the home of the Historic Cragun House. Built in 1893, it was once the home of Strange Nathaniel Cragun and his family. The family travelled the world, and their house is now a living history museum full of the pieces they collected from their travels as well as original furniture from the dwelling. This Victorian home is owned and maintained by the Boone County Historical Society and serves as headquarters for the organization. The Cragun House has been added to the National Register of Historic Places. Also listed on the National Register of Historic Places are the Boone County Courthouse and Oak Hill Cemetery.
=== Pharmacokinetics === LGD-4033 showed linear or dose-proportional pharmacokinetics across doses of 0.1 to 1 mg/day over 21 days of administration. Levels of LGD-4033 were 3-fold higher at day 21 compared to day 1, indicating significant accumulation with repeated administration. The mean area-under-curve levels of LGD-4033 on day 21 were 19 ng•day/mL at 0.1 mg/day, 85 ng•day/mL at 0.3 mg/day, and 238 ng•day/mL at 1 mg/day. The elimination half-life of LGD-4033 is 24 to 36 hours. Pharmacokinetic studies of LGD-4033 for purposes of doping detection have also been conducted.
The enzyme cystathionine γ-lyase (EC 4.4.1.1, CTH or CSE; also cystathionase; systematic name L-cystathionine cysteine-lyase (deaminating; 2-oxobutanoate-forming)) is an enzyme which in humans is encoded by the gene CTH. CTH enzymes break down cystathionine into cysteine, 2-oxobutanoate (α-ketobutyrate), and ammonia:
Pu(III), as Pu3+ (blue lavender) Pu(IV), as Pu4+ (yellow brown) Pu(V), as PuO+2 (light pink) Pu(VI), as PuO2+2 (pink orange) Pu(VII), as PuO3−5 (green)—the heptavalent ion is rare. The color shown by plutonium solutions depends on both the oxidation state and the nature of the acid anion. It is the acid anion that influences the degree of complexing—how atoms connect to a central atom—of the plutonium species. Additionally, the formal +2 oxidation state of plutonium is known in the complex [K(2.2.2-cryptand)] [PuIICp″3], Cp″ = C5H3(SiMe3)2. Preparation of plutonium(VIII) compounds such as the volatile tetroxide PuO4 has also been claimed, but their existence remains disputed. Metallic plutonium is produced by reacting plutonium tetrafluoride with barium, calcium or lithium at 1200 °C. Metallic plutonium is attacked by acids, oxygen, and steam but not by alkalis and dissolves easily in concentrated hydrochloric, hydroiodic and perchloric acids. Molten metal must be kept in a vacuum or an inert atmosphere to avoid reaction with air. At 135 °C the metal will ignite in air and will explode if placed in carbon tetrachloride.
Because of their costs, many transgender women cannot afford GnRH modulators and must use other, often less effective options for testosterone suppression. However, in countries with publicly funded health care, such as France, they are becoming more common: they are for instance prescribed as standard practice for transgender women in the United Kingdom, where the National Health Service (NHS) covers them. This is in contrast to the United States. Another drawback of GnRH modulators is that most of them are peptides and are not orally active, requiring administration by injection, implant, or nasal spray. However, non-peptide and orally active GnRH antagonists, elagolix (Orilissa) and relugolix (Relumina), were introduced for medical use in 2018 and 2019, respectively. But they are under patent protection and, as with other GnRH modulators, are very expensive at present. In adolescents of either sex, GnRH modulators can be used to suppress puberty. The eighth edition of the World Professional Association for Transgender Health's Standards of Care permit its use from Tanner stage 2 and recommends GnRH agonists as the preferred method of puberty blocking.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.